Dogwood Therapeutics Inc (DWTX)

$4.27 +0.54 (14.48%)
Market Cap 8.16M
Revenue (ttm) 0.00
Net Income (ttm) -12.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.24
Volume 1,997,100
Avg Vol 1,755,394
Day's Range N/A - N/A
Shares Out 1.91M
Stochastic %K 50%
Beta 1.99
Analysts Strong Sell
Price Target $20.50

Latest News on DWTX

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 11, 2025, 9:15 AM EDT - 9 days ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Apr 3, 2025, 9:00 AM EDT - 17 days ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31, 2025, 3:45 PM EDT - 20 days ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 18, 2025, 8:45 AM EDT - 4 weeks ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Mar 13, 2025, 9:00 AM EDT - 5 weeks ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Oct 7, 2024, 7:05 AM EDT - 7 months ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 9:15 AM EDT - 9 months ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 9:41 AM EDT - 9 months ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Jul 23, 2024, 9:15 AM EDT - 9 months ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 22, 2024, 1:30 PM EDT - 11 months ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 1 year ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 1 year ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

May 11, 2024, 11:44 PM EDT - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:45 AM EDT - 1 year ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

May 2, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Mar 26, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Feb 28, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 22, 2024, 9:00 AM EST - 1 year ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Jan 2, 2024, 7:05 AM EST - 1 year ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 11:21 AM EST - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:05 AM EST - 1 year ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 6, 2023, 7:05 AM EST - 1 year ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Oct 12, 2023, 7:05 AM EDT - 1 year ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 18, 2023, 7:05 AM EDT - 1 year ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Sep 12, 2023, 7:05 AM EDT - 1 year ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 14, 2023, 7:05 AM EDT - 1 year ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 10:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:05 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Aug 9, 2023, 7:05 AM EDT - 1 year ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Jul 17, 2023, 7:05 AM EDT - 1 year ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 25, 2023, 4:05 PM EDT - 2 years ago

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 15, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

Virios Therapeutics Announces First Quarter 2023 Financial Results

May 11, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2023 Financial Results

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 4, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Apr 24, 2023, 4:15 PM EDT - 2 years ago

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

Mar 7, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Feb 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

Jan 5, 2023, 7:00 AM EST - 2 years ago

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Nov 29, 2022, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript

Nov 14, 2022, 2:37 PM EST - 2 years ago

Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Nov 3, 2022, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Virios Therapeutics, Inc. Announces Closing of Public Offering

Sep 22, 2022, 4:15 PM EDT - 2 years ago

Virios Therapeutics, Inc. Announces Closing of Public Offering

Virios Therapeutics, Inc. Announces Pricing of Public Offering

Sep 19, 2022, 10:04 PM EDT - 2 years ago

Virios Therapeutics, Inc. Announces Pricing of Public Offering

Virios Therapeutics, Inc. Announces Proposed Public Offering

Sep 19, 2022, 4:05 PM EDT - 2 years ago

Virios Therapeutics, Inc. Announces Proposed Public Offering

Virios shares fall after sharing new clinical data about its fibromyalgia treatment candidate

Sep 19, 2022, 8:22 AM EDT - 2 years ago

Virios shares fall after sharing new clinical data about its fibromyalgia treatment candidate

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Sep 19, 2022, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia